TABLE 5.

Final population pharmacokinetic estimates from bootstrap results for ciprofloxacin plasma concentrations and dried blood spot concentrations in samples from nine healthy volunteers^a

Parameter	Value				P value
	Plasma parameter		Relative difference in DBS parameter
	Estimate	95% CI	Estimate	95% CI
Objective function value	−194.677	−251.926 to −160.894
Structural model parameters
MTTCIP (h)	0.57	0.33 to 0.667	0.98	0.87 to 1.06	0.46
NNCIP	7.3	1.9 to 12.8	0.78	0.57 to 1.89	0.55
CL/FCIP (liters/h/70 kg)	24.1	22.3 to 27.6	1.05	0.96 to 1.15	0.30
VC/FCIP (liters/70 kg)	108.1	87.5 to 131.1	0.79	0.68 to 0.95	0.032
Q/FCIP (liters/h/70 kg)	36.6	23.7 to 60.6	0.87	0.51 to 1.36	0.52
VP/FCIP (liters/70 kg)	81.7	62.8 to 111.5	1.24	0.97 to 1.61	0.09
Variable model parameters (shrinkage %)
IIV in MTTCIP (%)	25	12 to 93	0.95	0.75 to 1.33	0.73
IIV in NNCIP (%)	171	2 to 271	0.96	0.25 to 1.23	0.75
RV for ciprofloxacin (%)	18	13 to 21	1.53	1.08 to 2.01	0.024

^aMTT_CIP, mean transit time for CIP; NN_CIP, number of transit compartments for CIP; CL/F_CIP, clearance relative to bioavailability for CIP; V_C/F_CIP, central volume of distribution relative to bioavailability for CIP; Q/F_CIP, intercompartmental clearance relative to bioavailability for CIP; V_P/F_CIP, peripheral volume of distribution relative to bioavailability for CIP; IIV, interindividual variability; RV, residual variability. IIV is presented as $100\%\times \sqrt{\text{variability}\hspace{0.17em}\text{estimate}}$.